What is Nosopharm?
Nosopharm is a company operating within the enterprise sector, likely focused on developing innovative solutions or products. While the provided description appears to be extraneous data unrelated to Nosopharm, the company's funding history suggests a focus on scaling operations and advancing its technological or therapeutic offerings. The significant capital raised indicates a strong investor confidence in its business model and future prospects.
How much funding has Nosopharm raised?
Nosopharm has raised a total of $3.8M across 2 funding rounds:
Grant
$1.2M
Private Equity
$2.6M
Grant (2013): $1.2M, investors not publicly disclosed
Private Equity (2017): $2.6M led by Auriga Partners, Alto Invest, and Kreaxi
Key Investors in Nosopharm
Auriga Partners
Auriga Partners is a venture capital firm that likely focuses on investing in technology and innovation-driven companies, providing strategic capital to fuel growth.
Alto Invest
Alto Invest is a capital management company specializing in investments in fast-growing small and mid-sized companies, with extensive experience in managing private equity portfolios.
Kreaxi
Kreaxi is an investment management firm with a long history in equity financing for innovative startups, supporting entrepreneurs through seed, acceleration, and development phases with financial and strategic guidance.
What's next for Nosopharm?
With a major strategic investment bolstering its financial standing, Nosopharm is poised for accelerated growth. This capital infusion is anticipated to support key strategic objectives, potentially including research and development acceleration, market expansion, or the scaling of production capabilities. The company's ability to attract significant enterprise-level funding highlights its potential to disrupt its market and achieve significant milestones in the near future.
See full Nosopharm company page
